BRPI0611443B8 - medicamento compreendendo gestágeno e/ou estrógeno e 5-metil-(6s)-tetrahidrofolato, seu uso e seu processo de formulação, e kit - Google Patents
medicamento compreendendo gestágeno e/ou estrógeno e 5-metil-(6s)-tetrahidrofolato, seu uso e seu processo de formulação, e kitInfo
- Publication number
- BRPI0611443B8 BRPI0611443B8 BRPI0611443A BRPI0611443A BRPI0611443B8 BR PI0611443 B8 BRPI0611443 B8 BR PI0611443B8 BR PI0611443 A BRPI0611443 A BR PI0611443A BR PI0611443 A BRPI0611443 A BR PI0611443A BR PI0611443 B8 BRPI0611443 B8 BR PI0611443B8
- Authority
- BR
- Brazil
- Prior art keywords
- tetrahydrofolate
- methyl
- deficiency
- estrogen
- folate
- Prior art date
Links
- ZNOVTXRBGFNYRX-STQMWFEESA-N (6S)-5-methyltetrahydrofolic acid Chemical compound C([C@@H]1N(C=2C(=O)N=C(N)NC=2NC1)C)NC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 ZNOVTXRBGFNYRX-STQMWFEESA-N 0.000 title abstract 4
- 239000000262 estrogen Substances 0.000 title abstract 3
- 229940011871 estrogen Drugs 0.000 title abstract 3
- 239000000583 progesterone congener Substances 0.000 title abstract 3
- 239000003814 drug Substances 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 208000032170 Congenital Abnormalities Diseases 0.000 abstract 2
- 230000007547 defect Effects 0.000 abstract 2
- 230000007812 deficiency Effects 0.000 abstract 2
- 229940014144 folate Drugs 0.000 abstract 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 abstract 2
- 235000019152 folic acid Nutrition 0.000 abstract 2
- 239000011724 folic acid Substances 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 206010009269 Cleft palate Diseases 0.000 abstract 1
- 206010010356 Congenital anomaly Diseases 0.000 abstract 1
- 206010016880 Folate deficiency Diseases 0.000 abstract 1
- 102000005954 Methylenetetrahydrofolate Reductase (NADPH2) Human genes 0.000 abstract 1
- 108010030837 Methylenetetrahydrofolate Reductase (NADPH2) Proteins 0.000 abstract 1
- 102000004316 Oxidoreductases Human genes 0.000 abstract 1
- 108090000854 Oxidoreductases Proteins 0.000 abstract 1
- 230000007698 birth defect Effects 0.000 abstract 1
- 206010009259 cleft lip Diseases 0.000 abstract 1
- 239000003433 contraceptive agent Substances 0.000 abstract 1
- 230000002254 contraceptive effect Effects 0.000 abstract 1
- METQSPRSQINEEU-UHFFFAOYSA-N dihydrospirorenone Natural products CC12CCC(C3(CCC(=O)C=C3C3CC33)C)C3C1C1CC1C21CCC(=O)O1 METQSPRSQINEEU-UHFFFAOYSA-N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- METQSPRSQINEEU-HXCATZOESA-N drospirenone Chemical compound C([C@]12[C@H]3C[C@H]3[C@H]3[C@H]4[C@@H]([C@]5(CCC(=O)C=C5[C@@H]5C[C@@H]54)C)CC[C@@]31C)CC(=O)O2 METQSPRSQINEEU-HXCATZOESA-N 0.000 abstract 1
- 229960004845 drospirenone Drugs 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 229960005309 estradiol Drugs 0.000 abstract 1
- 229930182833 estradiol Natural products 0.000 abstract 1
- -1 ethinylene estradiol Chemical compound 0.000 abstract 1
- 210000001161 mammalian embryo Anatomy 0.000 abstract 1
- 230000001537 neural effect Effects 0.000 abstract 1
- 229940127234 oral contraceptive Drugs 0.000 abstract 1
- 239000003539 oral contraceptive agent Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
- 230000001681 protective effect Effects 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 230000002861 ventricular Effects 0.000 abstract 1
- 208000002670 vitamin B12 deficiency Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Gynecology & Obstetrics (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Nutrition Science (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pregnancy & Childbirth (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102005023301.5 | 2005-05-13 | ||
| DE102005023301A DE102005023301B4 (de) | 2005-05-13 | 2005-05-13 | Pharmazeutische Zusammensetzung enthaltend Gestagene und/oder Estrogene und 5-Methyl-(6S)-tetrahydrofolat |
| DE102006016285A DE102006016285A1 (de) | 2006-04-03 | 2006-04-03 | Pharmazeutische Zusammensetzung enthaltend Gestagene und/oder Estrogene und 5-Methyl-(6S)-tetrahydrofolat |
| DE102006016285.4 | 2006-04-03 | ||
| PCT/EP2006/004858 WO2006120035A2 (de) | 2005-05-13 | 2006-05-15 | Pharmazeutische zusammensetzung enthaltend gestagene und/oder estrogene und 5-methyl-(6s)-tetrahydrofolat |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0611443A2 BRPI0611443A2 (pt) | 2010-09-08 |
| BRPI0611443B1 BRPI0611443B1 (pt) | 2020-07-21 |
| BRPI0611443B8 true BRPI0611443B8 (pt) | 2021-05-25 |
Family
ID=37396913
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0611443A BRPI0611443B8 (pt) | 2005-05-13 | 2006-05-15 | medicamento compreendendo gestágeno e/ou estrógeno e 5-metil-(6s)-tetrahidrofolato, seu uso e seu processo de formulação, e kit |
Country Status (37)
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY29527A1 (es) | 2005-05-13 | 2006-12-29 | Schering Ag | Composicinn farmaccutica que contienen gestrgenos y/o estrngenos y 5-metil - (6s) - tetrhidrofolato. |
| CN101489563A (zh) * | 2006-07-06 | 2009-07-22 | 拜耳先灵医药股份有限公司 | 用于避孕和预防先天性畸形风险的药物制剂 |
| US8617597B2 (en) | 2006-07-06 | 2013-12-31 | Bayer Intellectual Property Gmbh | Pharmaceutical composition containing a tetrahydrofolic acid |
| EP1891959A1 (de) * | 2006-08-14 | 2008-02-27 | Bayer Schering Pharma Aktiengesellschaft | Pharmazeutische Zusammensetzung zur Kontrazeption und zur Verminderung des Risikos angeborener Fehlbildungen |
| DE112007001600A5 (de) * | 2006-07-06 | 2009-04-30 | Bayer Schering Pharma Aktiengesellschaft | Pharmazeutische Zusammensetzung zur Kontrazeption und zur Verminderung des Risikos angeborener Fehlbildungen |
| BRPI0810049A2 (pt) * | 2007-04-05 | 2015-05-05 | Bayer Schering Pharma Ag | Regime de drospirenona/17beta-estradiol, produto de combinação farmacêutica e kit para realizar esse regime |
| EA201070715A1 (ru) * | 2007-12-20 | 2011-02-28 | Тева Вимен'С Хелс, Инк. | Режимы дозирования, фармацевтические композиции и упаковки для экстренной контрацепции |
| TW200946542A (en) * | 2008-03-10 | 2009-11-16 | Vladimir Hanes | New drospirenone/17β-estradiol regimen, pharmaceutical combination product and kit for performing this regimen |
| WO2009112231A2 (en) * | 2008-03-10 | 2009-09-17 | Schuermann Rolf | New drospirenone/17beta-estradil regimen, pharmaceutical combination product and kit for performing this regimen |
| MX356702B (es) | 2010-04-15 | 2018-06-11 | Bayer Ip Gmbh | Formas de dosificación sólidas orales con dosis muy bajas para la hrt. |
| EP2383279A1 (en) | 2011-07-19 | 2011-11-02 | Pantarhei Bioscience B.V. | Process for the preparation of estetrol |
| EP2617422A1 (en) * | 2012-01-20 | 2013-07-24 | Isofol Medical AB | Anti-tumor activity of reduced folates like methylene-tetrahydrofolate, tetrahydrofolate or methyl-tetrahydrofolate |
| EP2781214A1 (en) * | 2013-03-22 | 2014-09-24 | Chemo Research, S.L. | Formulation of amorphous calcium L-5-methyltetrahydrofolate (L-5-MTHF-Ca) |
| CN104490887A (zh) * | 2014-09-04 | 2015-04-08 | 连云港金康和信药业有限公司 | (6s)-5-甲基-四氢叶酸钙盐的稳定药物组合物 |
| RS57328B1 (sr) | 2015-06-18 | 2018-08-31 | Mithra Pharmaceuticals S A | Orodisperzibilna dozna jedinica koja sadrži estetrolsku komponentu |
| LT3310345T (lt) | 2015-06-18 | 2021-06-25 | Estetra Sprl | Burnoje disperguojama tabletė, turinti estetrolio |
| NZ737945A (en) | 2015-06-18 | 2023-06-30 | Estetra Sprl | Orodispersible dosage unit containing an estetrol component |
| CA3178291A1 (en) | 2016-08-05 | 2018-04-12 | Estetra Srl | Method for the management of dysmenorrhea and menstrual pain |
| CN106336444A (zh) * | 2016-08-23 | 2017-01-18 | 国家卫生计生委科学技术研究所 | 一种新晶型炔雌醇 |
| CR20200486A (es) | 2018-04-19 | 2021-01-27 | Estetra Sprl | Compuestos y sus usos para aliviar los síntomas asociados a la menopausa |
| TWI801561B (zh) | 2018-04-19 | 2023-05-11 | 比利時商依思特拉私人有限責任公司 | 化合物及其用於緩解絕經相關症狀的用途 |
| TWI893101B (zh) | 2020-04-16 | 2025-08-11 | 比利時商埃斯特拉有限責任公司 | 具有降低之副作用之避孕組成物 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE61236B1 (en) * | 1986-07-15 | 1994-10-19 | American Home Prod | Combination dosage form for pre-menopausal women |
| ZA939565B (en) * | 1993-12-21 | 1994-08-11 | Applied Analytical Ind Inc | Method for preparing low dose pharmaceutical products. |
| US6083528A (en) * | 1995-09-28 | 2000-07-04 | Schering Aktiengesellschaft | Hormone replacement therapy method and hormone dispenser |
| CA2234817A1 (en) * | 1995-10-27 | 1997-05-01 | Mandana Asgharnejad | Wet granulation formulation of a growth hormone secretagogue |
| CN1122456C (zh) | 1996-01-31 | 2003-10-01 | 南亚拉巴马医学科学基金会 | 含有天然的还原叶酸盐异构体的食品和维生素制品 |
| CH693255A5 (de) * | 1997-06-13 | 2003-05-15 | Eprova Ag | Verwendung von Tetrahydrofolaten in der natürlichenstereoisomeren Form zur Herstellung einer pharmazeutischenZubereitung geeignet zur Beeinflussung des Homocystein-Spiegels. |
| US6326392B1 (en) | 1997-11-06 | 2001-12-04 | American Home Products Corporation | Anti-estrogen plus progestin containing oral contraceptives |
| UA68365C2 (en) * | 1997-11-06 | 2004-08-16 | Wyeth Corp | Peroral contraception by combination of anti-estrogen and progestin |
| CN1240387C (zh) * | 1998-04-17 | 2006-02-08 | 奥索一麦克尼尔药品公司 | 含有叶酸的药用组合物及其用途和给药系统 |
| US7014865B1 (en) | 1998-10-19 | 2006-03-21 | Merck Patent Gmbh | Natural formulation for the treatment and prevention of depression, containing St. John's Wort and derivatives of dihydro- and tetrahydrofolic acid |
| JP2002527484A (ja) * | 1998-10-19 | 2002-08-27 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | セントジョーンズワートならびにジヒドロおよびテトラヒドロ葉酸の誘導体を含有する、うつ病の治療および予防のための天然製剤 |
| CH693905A5 (de) | 1999-04-15 | 2004-04-15 | Eprova Ag | Stabile kristalline Salze von 5-Methyltetrahydrofolsäure. |
| HU225779B1 (en) | 1999-07-28 | 2007-08-28 | Chinoin Gyogyszer Es Vegyeszet | Pharmaceutical composition containing paracetamol and drotaverine and process for producing it |
| US6787531B1 (en) | 1999-08-31 | 2004-09-07 | Schering Ag | Pharmaceutical composition for use as a contraceptive |
| EP1598069B1 (en) | 1999-08-31 | 2009-04-22 | Bayer Schering Pharma Aktiengesellschaft | Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive |
| US6479545B1 (en) | 1999-09-30 | 2002-11-12 | Drugtech Corporation | Formulation for menopausal women |
| UA73119C2 (en) | 2000-04-19 | 2005-06-15 | American Home Products Corpoir | Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors |
| DE10022510A1 (de) * | 2000-05-10 | 2001-11-15 | Basf Ag | Zusammensetzungen enthaltend Folsäure und reduziertes Folat |
| US20020094970A1 (en) * | 2000-12-14 | 2002-07-18 | Ronenn Roubenoff | Compositions and methods for treating an arthritic condition |
| US20030045510A1 (en) * | 2000-12-15 | 2003-03-06 | Schloss Caroline Maxine | Estrogen-plus |
| EP1216713A1 (en) | 2000-12-20 | 2002-06-26 | Schering Aktiengesellschaft | Compositions of estrogen-cyclodextrin complexes |
| US20040220118A1 (en) * | 2001-02-02 | 2004-11-04 | Bland Jeffrey S. | Medical composition for balancing bodily processes |
| US20060034954A1 (en) * | 2001-02-02 | 2006-02-16 | Bland Jeffrey S | Medical composition for balancing bodily processes |
| CA2476940C (en) * | 2002-02-21 | 2011-11-01 | Bayer Intellectual Property Gmbh | Pharmaceutical compositions comprising one or more steroids, one or more tetrahydrofolate components and vitamin b12 |
| UY29527A1 (es) | 2005-05-13 | 2006-12-29 | Schering Ag | Composicinn farmaccutica que contienen gestrgenos y/o estrngenos y 5-metil - (6s) - tetrhidrofolato. |
-
2006
- 2006-05-11 UY UY29527A patent/UY29527A1/es not_active Application Discontinuation
- 2006-05-12 SV SV2006002527A patent/SV2008002527A/es active IP Right Grant
- 2006-05-12 AR ARP060101915A patent/AR054123A1/es not_active Application Discontinuation
- 2006-05-12 DO DO2006000110A patent/DOP2006000110A/es unknown
- 2006-05-12 GT GT200600200A patent/GT200600200A/es unknown
- 2006-05-12 TW TW095116905A patent/TWI380820B/zh active
- 2006-05-12 PE PE2006000504A patent/PE20061415A1/es active IP Right Grant
- 2006-05-15 MY MYPI20062228A patent/MY147362A/en unknown
- 2006-05-15 AT AT09075120T patent/ATE555791T1/de active
- 2006-05-15 KR KR1020077029090A patent/KR20080028369A/ko not_active Ceased
- 2006-05-15 NO NO20076408A patent/NO345807B1/no unknown
- 2006-05-15 CN CN2006800164109A patent/CN101198332B/zh not_active Expired - Lifetime
- 2006-05-15 RS RSP-2009/0327A patent/RS50972B/sr unknown
- 2006-05-15 SG SG201007499-5A patent/SG169973A1/en unknown
- 2006-05-15 EA EA200901393A patent/EA028530B1/ru not_active IP Right Cessation
- 2006-05-15 CN CN2010101564516A patent/CN101954083A/zh active Pending
- 2006-05-15 SI SI200631375T patent/SI2116249T1/sl unknown
- 2006-05-15 PL PL09075120T patent/PL2116249T3/pl unknown
- 2006-05-15 DK DK09075120.7T patent/DK2116249T3/da active
- 2006-05-15 PT PT06753787T patent/PT1888077E/pt unknown
- 2006-05-15 ES ES09075120T patent/ES2387525T5/es not_active Expired - Lifetime
- 2006-05-15 EP EP09075120.7A patent/EP2116249B2/de not_active Expired - Lifetime
- 2006-05-15 CA CA2608639A patent/CA2608639C/en not_active Expired - Fee Related
- 2006-05-15 HR HR20090418T patent/HRP20090418T1/xx unknown
- 2006-05-15 SI SI200630360T patent/SI1888077T1/sl unknown
- 2006-05-15 RS RS20120325A patent/RS52651B/sr unknown
- 2006-05-15 AT AT06753787T patent/ATE429917T1/de active
- 2006-05-15 ES ES06753787T patent/ES2325600T3/es not_active Expired - Lifetime
- 2006-05-15 DK DK06753787T patent/DK1888077T3/da active
- 2006-05-15 KR KR1020147010192A patent/KR101598735B1/ko not_active Expired - Lifetime
- 2006-05-15 AU AU2006245921A patent/AU2006245921A1/en not_active Abandoned
- 2006-05-15 EP EP06753787A patent/EP1888077B1/de not_active Expired - Lifetime
- 2006-05-15 EP EP10185658A patent/EP2298307A1/de not_active Withdrawn
- 2006-05-15 DE DE502006003617T patent/DE502006003617D1/de not_active Expired - Lifetime
- 2006-05-15 PT PT09075120T patent/PT2116249E/pt unknown
- 2006-05-15 PL PL06753787T patent/PL1888077T3/pl unknown
- 2006-05-15 BR BRPI0611443A patent/BRPI0611443B8/pt active IP Right Grant
- 2006-05-15 JP JP2008510518A patent/JP2008540482A/ja not_active Withdrawn
- 2006-05-15 EA EA200702349A patent/EA014664B1/ru active Protection Beyond IP Right Term
- 2006-05-15 WO PCT/EP2006/004858 patent/WO2006120035A2/de not_active Ceased
-
2007
- 2007-11-12 US US11/938,688 patent/US20080160004A1/en not_active Abandoned
- 2007-11-12 TN TNP2007000418A patent/TNSN07418A1/en unknown
- 2007-11-13 MA MA30367A patent/MA29448B1/fr unknown
- 2007-11-13 IL IL187340A patent/IL187340A/en active IP Right Grant
- 2007-11-16 CR CR9531A patent/CR9531A/es not_active Application Discontinuation
- 2007-12-11 EC EC2007008001A patent/ECSP078001A/es unknown
- 2007-12-12 ZA ZA2007/10811A patent/ZA200710811B/en unknown
-
2009
- 2009-07-28 CY CY20091100804T patent/CY1109261T1/el unknown
- 2009-12-14 ZA ZA2009/08894A patent/ZA200908894B/en unknown
- 2009-12-18 CL CL2009002187A patent/CL2009002187A1/es unknown
-
2010
- 2010-09-21 CL CL2010000989A patent/CL2010000989A1/es unknown
-
2012
- 2012-08-02 CY CY20121100689T patent/CY1114403T1/el unknown
-
2013
- 2013-02-18 JP JP2013029277A patent/JP5883810B2/ja not_active Expired - Lifetime
-
2015
- 2015-12-10 US US14/965,173 patent/US10463666B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20076408L (no) | Farmasoytisk preparat som inneholder gestagener og/eller ostrogener og 5-metyl-(6S)-tetrahydrofolat | |
| US8349820B2 (en) | Use of estradiol valerate or 17β-estradiol in combination with dienogest for oral therapy to maintain and/or increase feminine libido | |
| Köhler et al. | A dose-ranging study to determine the efficacy and safety of 1, 2, and 4 mg of dienogest daily for endometriosis | |
| De Leo et al. | Effect of oral contraceptives on markers of hyperandrogenism and SHBG in women with polycystic ovary syndrome | |
| BR0107216A (pt) | Compostos estroprogestacionais tópicos com efeito sistêmico | |
| PE20080273A1 (es) | Composicion farmaceutica que contiene un progestageno, un estrogeno y un acido tetrahidrofolico | |
| BRPI0512991A (pt) | uso de uma progestina, kit farmaceuticamente útil adaptado para a administração oral diária, e, método de contracepção em uma fêmea em idade de parto | |
| CO6251259A2 (es) | Formulaciones farmaceuticas de estriol en baja dosis | |
| CL2007001961A1 (es) | Composicion farmaceutica que contiene a) 2,0 mg de dienogest y 0,015 mg de etinilestradiol y (6s)-5-metil-tetrahidrofolato y uno o mas excipiente/vehiculos; kit; uso para la anticoncepcion femeneina y reducir el riesgo d malformaciones congenitas debidas a la falta de folato en el embarazo. | |
| BR0014979A (pt) | Composição hormonal e sua utilização | |
| BRPI0408944A (pt) | método para fornecer um benefìcio de redução de esteróide com um inibidor de ciclooxigenase-2 e composições com este | |
| ES2438734T3 (es) | Anticonceptivo que contiene ácido fólico | |
| O'Connell et al. | Pharmacology of hormonal contraceptives and acne | |
| ES2432378T3 (es) | Forma de administración para la anticoncepción hormonal | |
| PE20240811A1 (es) | Metodo para tratar la endometriosis y proporcionar una anticoncepcion eficaz | |
| JP4908399B2 (ja) | 天然エストロゲンに基づく段階型避妊製剤 | |
| US8383165B1 (en) | Composition and method for fertility therapy using nutritional supplements | |
| BRPI0410707A (pt) | composição que compreende antagonistas de receptores de progesterona e antiestrogênios puros para a profilaxia e tratamento de doenças dependentes de hormÈnios | |
| Sah et al. | Effects of long-term administration of the antiaging hormone dehydroepiandrosterone sulfate on rat prostates and testes as androgen-dependent organs | |
| UA92491C2 (ru) | Фармацевтическая композиция, которая содержит гестагены и/или эстрогены и 5-метил-(6s)-тетрагидрофолат | |
| Mikhail et al. | Evidence-based review of topical treatments for psoriasis | |
| BRPI0606724A2 (pt) | preparação farmacêutica para contracepção | |
| TW200946542A (en) | New drospirenone/17β-estradiol regimen, pharmaceutical combination product and kit for performing this regimen | |
| CU20070252A7 (es) | Composición farmacéutica que contiene drospirenona, etinilestradiol y la sal de calcio del ácido 5-metil-(6s)-tetrahidrofólico | |
| Kubba et al. | Hormonal therapy of acne |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25D | Requested change of name of applicant approved |
Owner name: MERCK EPROVA AG (CH) , BAYER PHARMA AKTIENGESELLSC |
|
| B25A | Requested transfer of rights approved |
Owner name: MERCK EPROVA AG (CH) , BAYER INTELLECTUAL PROPERTY |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 21/07/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/05/2006 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B25G | Requested change of headquarter approved |
Owner name: MERCK EPROVA AG (CH) ; BAYER INTELLECTUAL PROPERTY GMBH. (DE) |